Drug Utilization Review Board Meeting Minutes
May 23, 2012

The West Virginia Medicaid Drug Utilization Review (DUR) Board meeting was called to order with the following in attendance:

Members Present:
Ernest Miller, D.O., Chairman
Greenbrier Almond, M.D.
Myra Chiang, M.D.
David Elliott, PharmD
Lester Labus, M.D.
KC Lovin, PA-C
Mary Nemeth-Pyles, M.S.N., R.N., C.S.
Pat Regan, PharmD
Chris Terpening, PharmD, Ph.D.
John R. Vanin, M.D.

Members Absent:
Scott Brown, R.Ph, Co-Chairman
Randall James, D.O.
Kerry Stitzinger, R.Ph.

DHHR/BMS Staff Present:
Vicki Cunningham, R.Ph., DUR Coordinator
Bill Hopkins, Pharmacy Operations Manager
Teresa Harrison, Secretary, Bureau for Medical Services

Contract Staff:
Steve Small, M.S.,R.Ph.,Rational Drug Therapy Program
Eric Sears, R.Ph., Molina Medicaid Solutions
Douglas Brink, PharmD, Xerox State Healthcare
Victoria Mariani, R.N., Xerox State Healthcare

I. INTRODUCTIONS

Dr. Ernest Miller, Chairman, welcomed everyone to the Board meeting. Members of the Board and interested parties introduced themselves.

II. APPROVAL OF THE FEBRUARY 15, 2012 MINUTES

A motion was made to accept the minutes of the February 15, 2012, DUR Board meeting with one correction John R. Vanin, M.D. was listed as present for the meeting in error. The motion was seconded and passed unanimously.

III. OLD BUSINESS

A. Hepatitis C Antiretroviral Drugs-PA Criteria Addition

1. **Incivek (telaprevir)** -The Board approved the changes to the PA criteria as written.
   See Attachment A
2. **Victrelis (boceprevir)** - The Board approved the changes to the PA criteria as written.
   See Attachment B

B. Makena Policy-Manufacturer's Representative

The manufacturer's representative scheduled to speak was not present. Ms. Cunningham called attention to the Bureau's statement regarding coverage of Makena and language from the FDA regarding compounded hydroxyprogesterone caproate (CHC).

See Attachment C

IV. NEW BUSINESS

A. Representative from Novartis Pharmaceuticals-Immunosuppressive Agents.

Sarjita Naik, Novartis Pharmaceuticals spoke about the immunosuppressants, Zortress and Myfortic.

B. Update from P&T Committee meeting April 25, 2012

1. **Analgesics, Narcotics Short Acting-**The Board approved the PA criteria as written.
2. **Angiotensin Modulators-**The Board approved the PA criteria as written.
3. **Anticonvulsants-**The Board approved the PA criteria as written.
4. **Beta-Blockers-** The Board approved the PA criteria as written.
5. **Hypoglycemics, Incretin Mimetics/Enhancers-**
   Byetta, **Victoza**, and **Bydureon-**The Board requested that the PA criteria be rewritten to read:
   Approval will be given for six (6) months for patients with 1) Diagnosis of Type 2 Diabetes, 2) Previous history of a thirty (30) day trial of metformin, 3) Concurrent therapy with a basal insulin and 4) No history of pancreatitis. Initial approval will be given for six months with no $HgBA_1C$ levels required. For re-authorization, $HgBA_1C$ levels must be less than or equal to (≤) 7.
   Symlin-The Board requested that the PA criteria be rewritten to say history of **bolus** insulin utilization, instead of history of insulin utilization.
   Jentadueto-The Board approved the PA criteria as written.
   Janumet XR-The Board approved the PA criteria as written.
6. **Immunosupressives-**The Board approved the PA criteria as written. Members currently on non-preferred agents will be grandfathered.
7. **Ophthalmic Antibiotic-Steroid Combinations-**The Board approved the PA criteria as written.
8. **Ophthalmic, Glaucoma Agents-**The Board approved the PA criteria as written.

   See Attachment D

C. Oral Oncology Agents-Prior Authorization Criteria and Dosage Limits

Ms. Cunningham provided a handout of available oral oncology agents, their approved FDA indications and maximum dosages. The Board requested cost and utilization information in order to make an informed decision about whether or not to include these agents in the prior authorization program. Mrs. Cunningham will provide the information at the next DUR Board meeting.

See Attachment E

D. Kalydeco- The Board approved the PA criteria as written.

See Attachment F

E. Kuvan- The Board approved the PA criteria as written.
See Attachment G

F. Increlex- The Board approved the PA criteria as written.
See Attachment H

V. REPORTS

A. Rational Drug Therapy Program. Steve Small, Director of the Rational Drug Therapy Program (RDTP), distributed a handout of his slide presentation. Mr. Small summarized the prior authorization process and top edits and overrides for February, March, and April 2012. He then introduced data on the prior authorizations generated by the change in the status of Adderall XR to non-preferred. Prescriptions for members under eighteen (18) years of age are grandfathered until July 1, 2012. These members will need to change to a preferred product or obtain a prior authorization as of that date. He also discussed the Hepatitis Antiretroviral Agents, Incivek and Victrelis, and the problematic issues with lab test sensitivities. In addition, Mr. Small presented data on Suboxone long term treatment and discussed the problem of weaning members off Suboxone.
See Attachment H

B. Xerox State Healthcare (formerly ACS State Healthcare). Douglas Brink, PharmD from Xerox State Healthcare, discussed recent Retrospective DUR activities.

1. Antibiotic Newsletter was mailed in January 2012 to 4,860 providers.
2. Diabetes Management Population-Based Intervention was mailed in March, 2012 to 717 providers targeting 16,485 patients.
3. Chronic Non-Malignant Pain Population-Based Intervention was mailed in March 2012 to 629 providers targeting 1,725 patients.
4. ADHD Management Newsletter was mailed in April 2012 to 4,767 providers.
5. Adderall PDL change notification letters were mailed in April, 2012 to 310 providers.

Dr. Brink introduced future provider interventions regarding **Overutilization of Antibiotics**, and **Depression: Effective Antidepressant Management**. Summaries of the proposed interventions and samples of the letters to providers were distributed. The Board approved the provider interventions as presented.

C. Molina Fourth Quarter Report. Eric Sears, R.Ph, Molina Medicaid Solutions gave an overview of the Molina Fourth Quarter Report.

VI. OTHER BUSINESS-OPEN TO THE FLOOR.

Ms. Cunningham announced that there are plans for moving the disabled population and pharmacy benefits into managed care later this year.

VII. NEXT MEETING AND ADJOURNMENT.

A motion was made and seconded that the meeting be adjourned. All were in favor. The meeting was concluded at 6:00 p.m. The next meeting will be held on Wednesday, September 19, 2012 from 4:00 p.m.-6:00 p.m.

Respectfully submitted,

Victoria Mariani R.N., Xerox State Healthcare